Tue, Oct 21, 2014, 9:50 AM EDT - U.S. Markets close in 6 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

annickawaechter 231 posts  |  Last Activity: 17 hours ago Member since: Mar 28, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Remember ceezad?????

    by hebmasterll 19 hours ago
    annickawaechter annickawaechter 17 hours ago Flag

    I agree hebmaster, the animal study is finished with promissing results, now it's time to make money

    Sentiment: Strong Buy

  • Reply to

    If this was a scam

    by alexander.johannes Oct 18, 2014 1:12 PM
    annickawaechter annickawaechter 18 hours ago Flag

    back on top

    Sentiment: Strong Buy

  • Reply to

    The strength of ampligen and alferon

    by annickawaechter Oct 18, 2014 3:20 PM
    annickawaechter annickawaechter Oct 18, 2014 10:17 PM Flag

    In conclusion: you did not tell the trutj about the role of TLR signaling in filovirus infection! Ampligen/alferon might just work fine in it and that is why six biosecurity labs level 4 are testing it on ebola!!!!

    Sentiment: Strong Buy

  • Reply to

    The strength of ampligen and alferon

    by annickawaechter Oct 18, 2014 3:20 PM
    annickawaechter annickawaechter Oct 18, 2014 10:13 PM Flag

    a recent study by Leung et al. suggests that cells utilizing TLR-mediated antiviral pathways such as for example plasmacytoid dendritic cells are not prone to the inhibitory effects of VP35 EBOV than cells relying on RIG-like signaling pathways.

    Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol. 2011 doi: 10.1038/icb.2010.169

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Oct 18, 2014 5:08 PM Flag

    In Germany people don't wast their time on a message board if they aren't long or short. I guess you must be short

    Sentiment: Strong Buy

  • Reply to

    If this was a scam

    by alexander.johannes Oct 18, 2014 1:12 PM
    annickawaechter annickawaechter Oct 18, 2014 4:10 PM Flag

    Link:
    http://www.prohealth.com/library/showarticle.cfm?libid=18542

    Sentiment: Strong Buy

  • Reply to

    If this was a scam

    by alexander.johannes Oct 18, 2014 1:12 PM
    annickawaechter annickawaechter Oct 18, 2014 3:59 PM Flag

    I am writing to you on behalf of myself and the vast number of patients who suffer from myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), a disease classified by the FDA in the category of serious or life threatening. The arbitrary application by the FDA of the rules relating to drug approval seems to give more weight to the front-page news than the actual gravity of a disease. I am confounded at the FDA’s decision to approve the use of Bexsero at Princeton University to prevent further cases of meningococcus B causing meningitis while at the same time failing to provide Ampligen for ME/CFS patients earlier this year.

    As an attorney who practiced at the world’s largest law firm, I am familiar with the application of laws and regulations, as well as the use of fair and responsible judgment. Unfortunately, I was forced to leave my position when I got sick with this mercilessly debilitating and unrelenting disease, ME/CFS.

    The FDA’s decision to allow the import of Bexsero into the United States for the use in a vaccination campaign for approximately eight thousand students at Princeton University in an effort to prevent potential mass deaths, or other tragic cases, like serious complications such as the amputations in the case of one UCSB student, from meningitis implies one of two things. Either the FDA is concerned for the health and welfare of patients in the face of a serious and potentially life-threatening disease or the FDA applies the law in an egregiously unequal and arbitrary manner when it comes to severely ill patient populations. My question to you, Dr. Woodcock, is why the FDA did not apply same concern and medical judgment it is demonstrating for the Princeton cohort to its decision about Ampligen.

    Ampligen was denied approval by the FDA in February of this year, even though the FDA’s advisory committee voted in December of last year that the drug was safe. The committee split its vote on the question of efficacy, in all likelihood due to a lack of understanding by the agency of the severity of the disease and the significance of clinical improvements for patients receiving the drug as part of clinical trials. In fact, Dr. Theresa Michele, FDA clinical team leader for the Ampligen decision, admitted and stressed, at the April FDA Drug Development Meeting, that she had not previously been aware of the symptoms of ME/CFS as clearly as she was as a result of listening to patients’ testimony at the April meeting. I cannot help but wonder if the decision not to approve Ampligen might have differed had there been a clearer understanding of the seriousness of the disease by the FDA before the decision was made.

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Oct 18, 2014 3:20 PM Flag

    The two platform drugs of Hemispherx, Alferon(R) N and Ampligen(R), have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. First, both drugs have mechanisms of action, which are multifaceted by working thru cellular "molecular cascades" (i.e. multiple mediators which protect cells from viral pathogenesis) rather than target viral targets whose specificity is vulnerable to mutational change. Cellular antiviral pathways of innate immunity are not subject to the mutational pressures of rapidly dividing viruses, which suggests that - even in the face of viral mutation - products activating innate immunity may continue to show biological activity. For example, work at the Japanese National Institutes of Health (Journal of Infectious Diseases (2007) 196:1313) indicated that Ampligen(R) affords wider cross-clade protection apparently through epitope expansion when added to existing influenza vaccines, an observation which has recently been extended clinically at the University of Alabama Clinical Research Center (Vaccine (2014) http://dx.doi.org/10.1016/j.vaccine.2014.07.078). Secondly, both drugs are unusually effective against highly virulent viruses such as SARS, as noted by Singapore investigators (Emerging Infectious Disease (2004) 10(4):581) and independent US health researchers (Virology (2009) 395:210). Alferon(R) N has also demonstrated superior potency to that shown by recombinant alpha interferons (AIDS Research Human Retroviruses.1993; 9:1115-111) and ability to afford apparent clinical benefit in the presence of antibodies against recombinant interferons (Journal of Interferon and Cytokine Research.2012; 32:95-9). Ampligen(R) is also active against the Respiratory Syncytial Virus (RSV) which is organized in a pattern very similar to EBOV genome and both the viruses are "negative sense" RNA viruses.

    Sentiment: Strong Buy

  • Reply to

    Is CFS a big market?

    by mdpetrosky Oct 18, 2014 2:33 PM
    annickawaechter annickawaechter Oct 18, 2014 3:00 PM Flag

    Currently more than one million people in the US suffer from CFS

    Sentiment: Strong Buy

  • Reply to

    If this was a scam

    by alexander.johannes Oct 18, 2014 1:12 PM
    annickawaechter annickawaechter Oct 18, 2014 1:42 PM Flag

    Chronic Fatigue Syndrome.... Ampligen is currently the only drug that has the potential to treat CFS. Currently the company is re-evaluating phase 3results because a subset of the population has had very significant results on Ampligen, namely the subset which has no/insufficient NK cells or natural killer cells which help the immune system. Because Ampligen helped the people in this subset that good, people are standing up for Ampligen so it will be FDA approved. Results are expected in 2015.
    You should read and wat h the recorded presentation of the company at the rodman and renshaw conference, their science and potential is quite unique and convincing. You can watch it on the company's website.

    Sentiment: Strong Buy

  • Reply to

    I believe this closed a hair up

    by lescolddew Oct 15, 2014 4:23 PM
    annickawaechter annickawaechter Oct 15, 2014 4:30 PM Flag

    indeed heb closed green

    Sentiment: Strong Buy

  • Reply to

    HEB fought the FDA, and the FDA won....

    by biotechninja888 Oct 15, 2014 4:13 AM
    annickawaechter annickawaechter Oct 15, 2014 5:01 AM Flag

    Analyst target $3/share
    I have more confidence in analysts than in ninja's

    Sentiment: Strong Buy

  • Reply to

    HEB fought the FDA, and the FDA won....

    by biotechninja888 Oct 15, 2014 4:13 AM
    annickawaechter annickawaechter Oct 15, 2014 4:17 AM Flag

    Additional study results on CFS will be ready in 2015. It is already clear the FDA decided that Ampligen is safe. The fda panel decided positive on safety.
    It will be approved for CFS next year and meanwhile the tension is high on Ebola.
    Analyst target of $3/share is too low.

    Sentiment: Strong Buy

  • Reply to

    accumulation going on for a week already

    by annickawaechter Oct 13, 2014 3:04 PM
    annickawaechter annickawaechter Oct 13, 2014 3:05 PM Flag

    that's 4 dollar/share which is extremely conservative

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Oct 10, 2014 3:55 PM Flag

    shorts are spamming... they better take their time to initiate an order to cover, because Monday there could be huge news. The last quarter the volume almost doubles and red went green

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Oct 10, 2014 3:38 PM Flag

    Maybe it is just an end of the week spike, but if it is due to Ebola news I wouldn't even wish it to my biggest enemy to stay short.

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Oct 10, 2014 3:28 PM Flag

    gooooo $$$$$

    Sentiment: Strong Buy

  • Reply to

    Solar Alliance...

    by freshcope99 Sep 21, 2014 8:52 PM
    annickawaechter annickawaechter Oct 9, 2014 3:41 PM Flag

    all I know is that finavera did make a great deal taking them over

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Oct 9, 2014 9:03 AM Flag

    BacK on top

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Oct 9, 2014 4:16 AM Flag

    Maybe both, because both work on a different pathway to survive ebola.
    I will be buying nnvc tomorrow, i am already holding heb

    Sentiment: Strong Buy

CLSN
2.61+0.01(+0.52%)9:39 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.